Bristol Myers Squibb Quick Ratio (BMY) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Bristol myers Squibb Company  (NYSE: BMY)

Bristol Myers Squibb's Quick Ratio

BMY's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Bristol Myers Squibb's Cash & cash equivalent grew by 13.68 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Bristol Myers Squibb's Quick Ratio to 0.67, Quick Ratio remained below Bristol myers Squibb Company average.

Within Major Pharmaceutical Preparations industry 381 other companies have achieved higher Quick Ratio than Bristol Myers Squibb in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 2586, from total ranking in the second quarter 2026 at 3433.

Explain Quick Ratio?
How much Cash & cash equivalents BMY´s has?
What are BMY´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BMY/financial-strength
https://api.csimarket.com/api/v1/companies/BMY/fundamentals
https://api.csimarket.com/api/v1/companies/BMY/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BMY Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -33.35 %
Y / Y Cash & cash equivalent Change -23.76 %
Quick Ratio MRQ 0.67
BMY's Total Ranking # 2586
Seq. Current Liabilities Change 0.5 %
Seq. Cash & cash equivalent Change 13.68 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 382
Healthcare Sector # 702
Overall Market # 2358


Quick Ratio Statistics
High Average Low
3.19 0.81 0.26
(Sep 30 2019)   (March 31, 2008)




Financial Statements
Bristol Myers Squibb's Current Liabilities $ 18,753 Millions Visit BMY's Balance sheet
Bristol Myers Squibb's Cash & cash equivalent $ 12,581 Millions Visit BMY's Balance sheet
Source of BMY's Sales Visit BMY's Sales by Geography


Cumulative Bristol Myers Squibb's Quick Ratio

BMY's Quick Ratio for the trailling 12 Months

BMY Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -21.78 %
Y / Y Cash & cash equivalent TTM Growth -15.05 %
Quick Ratio TTM 0.55
Total Ranking TTM # 2018
Seq. Current Liabilities TTM Growth -10.39 %
Seq. Cash & cash equivalent TTM Growth -8.05 %

Quick ratio ranking by company, industry and sector >> Back to BMY Financial Strength Comparisons >> Go to Compare BMY Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Bristol Myers Squibb's average Cash & cash equivalent, this led to increase in in Bristol Myers Squibb's Quick Ratio to 0.55, Quick Ratio remained below BMY average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 440 other companies have achieved higher Quick Ratio than Bristol Myers Squibb. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4053.

Explain Quick Ratio?
How much Cash & cash equivalents BMY´s has?
What are BMY´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 441
Healthcare Sector # 904
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
1.84 0.58 0.19
(Sep 30 2019)   (June 30. 2013)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Mustang Bio inc   1.80 $ 14.276  Millions$ 7.947  Millions
Biovie Inc   1.78 $ 7.733  Millions$ 4.350  Millions
Alnylam Pharmaceuticals Inc   1.74 $ 3,587.255  Millions$ 2,063.006  Millions
Mallinckrodt Plc  1.74 $ 1,085.600  Millions$ 624.900  Millions
Insmed Inc  1.73 $ 1,146.626  Millions$ 662.181  Millions
Nkarta Inc   1.72 $ 48.354  Millions$ 28.072  Millions
Mannkind Corporation  1.67 $ 181.525  Millions$ 108.524  Millions
Verastem Inc   1.67 $ 172.801  Millions$ 103.328  Millions
Agios Pharmaceuticals Inc   1.66 $ 128.549  Millions$ 77.588  Millions
Bridgebio Pharma Inc   1.57 $ 1,538.855  Millions$ 977.237  Millions
Arcutis Biotherapeutics Inc   1.51 $ 259.460  Millions$ 172.357  Millions
Regeneron Pharmaceuticals Inc   1.50 $ 9,301.100  Millions$ 6,202.100  Millions
Emergent Biosolutions Inc   1.44 $ 175.700  Millions$ 122.000  Millions
Arbutus Biopharma Corp  1.39 $ 337.490  Millions$ 241.933  Millions
Compass Pathways Plc  1.36 $ 443.979  Millions$ 325.863  Millions
Sarepta Therapeutics Inc   1.34 $ 878.776  Millions$ 656.353  Millions
Zai Lab Limited  1.32 $ 559.658  Millions$ 424.249  Millions
Urogen Pharma Ltd   1.31 $ 96.901  Millions$ 74.031  Millions
Ani Pharmaceuticals Inc  1.28 $ 420.758  Millions$ 328.717  Millions
Vertex Pharmaceuticals Inc  1.26 $ 6,303.300  Millions$ 5,000.300  Millions
Nature s Sunshine Products inc   1.22 $ 89.377  Millions$ 73.488  Millions
Ovid Therapeutics Inc   1.16 $ 13.811  Millions$ 11.858  Millions
Filana Therapeutics Inc   1.12 $ 46.990  Millions$ 41.946  Millions
Phathom Pharmaceuticals Inc   1.06 $ 184.558  Millions$ 174.902  Millions
Eton Pharmaceuticals Inc   1.03 $ 55.628  Millions$ 54.095  Millions
Akebia Therapeutics Inc   0.98 $ 159.254  Millions$ 162.349  Millions
Acadia Pharmaceuticals Inc   0.97 $ 322.365  Millions$ 332.217  Millions
Alkermes Plc   0.97 $ 631.314  Millions$ 651.933  Millions
Geron Corporation  0.94 $ 69.794  Millions$ 74.248  Millions
Mirum Pharmaceuticals Inc   0.86 $ 243.188  Millions$ 283.080  Millions

Date modified: 2026-10-30T16:58:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.